Last mentioned: Mar 17, 2026
Data Readout
Anticipated top-line data from the Phase 3 VERIFY clinical trial.
Q4 Earnings
Scheduled announcement of quarterly financial results and pipeline update.
Quarterly Earnings
Expected announcement of financial results and pipeline updates for PTGX and OEZVY.
BofA Price Target Hike
Bank of America increases price target, highlighting R&D productivity and MedTech growth.
BofA Target Increase
Bank of America raises price target based on pharmaceutical and MedTech pipeline strength.
Institutional Rebalancing
Richard Bernstein Advisors and Rathbones Group PLC report reduced holdings in JNJ.
Fast-Track Approval
USFDA grants approval for Tecvayli-Darzalex combination via fast-track voucher program.
Fast-Track Approval
FDA approves Tecvayli-Darzalex combination for blood cancer treatment.
12-Month High
JNJ shares reach a new yearly peak following FDA approval for multiple myeloma combo.
FDA Approval & 12-Month High
JNJ receives FDA approval for multiple myeloma combo and stock hits a yearly peak.
Institutional Exit Revealed
13F filings reveal a $170 million divestment by a major institutional fund.
Institutional Exit
SEC filings reveal a $170 million position liquidation by a major fund.
TGA Approval
Australian regulatory body approves the Virtual Nodule Clinic for clinical use.
120% Gain Milestone
PTGX stock reaches a 120% gain milestone from its 52-week low.
J&J Partnership Milestone
Johnson & Johnson advances JNJ-2113 into late-stage trials, validating oral peptide tech.
Pipeline Update
Initial Phase 1 data released for LB2102 in solid tumors at a major medical conference.
120% Rally
Stock price reaches a 12-month peak following sustained clinical momentum.
JNJ-2113 Phase 3 Progress
Johnson & Johnson advances oral peptide JNJ-2113 into pivotal trials.
Phase 3 Data Release
Positive Phase 3 data for rusfertide in polycythemia vera triggers initial stock rally.
Manufacturing Expansion
Obelisc facility in Belgium reaches full operational status for clinical and commercial supply.
As the market enters March 2026, investors are increasingly turning to 'Dividend Kings'—companies with over 50 consecutive years of dividend increases—as a defensive hedge against lingering volatility. This briefing analyzes the top three picks for the month: Procter & Gamble, Johnson & Johnson, and Coca-Cola, highlighting their resilience and compounding potential.
Protagonist Therapeutics (PTGX) is set to report quarterly earnings this Wednesday, with investors focused on the commercial trajectory of its Takeda-partnered rusfertide. The results come at a critical juncture as the company transitions from a clinical-stage R&D house to a commercially-oriented biotech entity.
Protagonist Therapeutics (PTGX) is scheduled to release its quarterly earnings on Wednesday, March 18, 2026, with investors focused on the commercialization path for rusfertide and the Phase 3 progress of its oral IL-23 receptor antagonist, icotrokinra. The results will provide a critical update on the company's transition from a clinical-stage biotech to a potential commercial powerhouse in the immunology and hematology sectors.
Bank of America has raised its price target for Johnson & Johnson, citing robust growth in the company's pharmaceutical and MedTech pipelines. The upgrade follows a series of FDA approvals and a strategic pivot toward high-margin innovative medicine after the Kenvue spinoff.
Bank of America has raised its price target for Johnson & Johnson, citing a robust outlook for the company's Innovative Medicine and MedTech divisions. The upgrade reflects growing confidence in JNJ's oncology pipeline and its ability to navigate upcoming patent expirations for key assets.
Bank of America has raised its price target for Johnson & Johnson (JNJ), citing a strengthened outlook for the company's pharmaceutical and MedTech pipelines. The upgrade reflects growing investor confidence in JNJ's post-Kenvue strategy, which prioritizes high-margin innovation in oncology, immunology, and surgical robotics.
A new DelveInsight report projects a steady 7% CAGR for the minimally invasive surgical devices (MISD) market through 2034, driven by technological leaps in robotics and a global shift toward outpatient care. This expansion reflects a broader healthcare transition prioritizing reduced recovery times and improved clinical outcomes over traditional open surgeries.
Legend Biotech and Core Molding Technologies released their full-year 2025 financial results, highlighting a period of strategic expansion and operational resilience. While Legend Biotech continues to scale its CAR-T therapy footprint, Core Molding demonstrated steady performance in the industrial manufacturing sector.
Legend Biotech (LEGN) has announced its fourth-quarter and full-year 2025 financial results, showcasing a significant surge in net trade sales for its CAR-T therapy, Carvykti. The company continues to expand its manufacturing footprint and advance its pipeline in solid tumors, solidifying its position as a leader in the cell therapy market.
Optellum has received regulatory clearance from Australia’s Therapeutic Goods Administration (TGA) for its AI-driven lung nodule management platform. The approval enables the deployment of the Virtual Nodule Clinic to help Australian clinicians identify and treat early-stage lung cancer more effectively.
Protagonist Therapeutics has seen its stock price more than double following clinical breakthroughs in its oral peptide portfolio, yet a major institutional investor has liquidated a $170 million position. This tactical exit highlights the tension between clinical optimism and institutional profit-taking as the company nears critical Phase 3 milestones.
Protagonist Therapeutics shares have soared 120% following clinical and regulatory milestones, but a recent $170 million institutional exit is raising questions about the stock's near-term ceiling. The move highlights a growing divergence between retail momentum and institutional profit-taking in the biotech sector.
Protagonist Therapeutics has seen its share price skyrocket by 120% following significant clinical and regulatory milestones, yet a major institutional investor has disclosed a $170 million exit. This divergence highlights a classic 'sell the news' moment or strategic rebalancing amidst a period of high valuation for the peptide-based drug developer.
A series of recent clinical studies have directly challenged the public health assertions made by Robert F. Kennedy Jr. regarding vaccines, Tylenol, and antidepressants. These findings underscore a growing tension between evidence-based medicine and the policy platform of the potential future leadership at the Department of Health and Human Services.
Genmab A/S reported full-year 2025 revenue of $3.72 billion, missing analyst estimates despite strong growth in its core oncology portfolio. The company is prioritizing long-term growth through its $1.8 billion ProfoundBio acquisition and the global rollout of Epkinly, leading to a temporary contraction in net profit margins.
Genmab reported full-year 2025 revenue of $3.72B, missing analyst estimates by $50M, while initiating a robust 2026 outlook focused on proprietary oncology assets. Despite a dip in full-year profit, the company is accelerating its transition from a royalty-dependent model to a self-sustaining commercial powerhouse.